Medlab Clinical Ltd (ASX:MDC) managing director & CEO Sean Hall speaks to Proactive Investors about the pharmaceutical company’s new European subsidiary and its development of products to treat chronic disease.
Medlab has 30 nutraceutical products (pharmaceutical-grade and standardised nutrients) globally, with another 10 in development, and two cannabis-based medicines NanaBis and NanaBidial which contain formulations of tetrahydrocannabinol and cannabidiol.
“There are financial advantages and concessions potentially available with the European Medicines Agency (EMA), if there is a European subsidiary,” Hall says.
He continues, “we are now exchanging paperwork with the EMA and trying to formalise what could be a significant discount on their drug registration fees moving forward, so that we can move beyond pathway development and actually formalising it with the regulatory agency for approved claims in Europe.”